X

Biogen (NASDAQ: BIIB): Q4 2019 Earnings Snapshot

— Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter 2019 adjusted earnings of $8.34 per share versus $8.02 per share expected.

— Total revenues increased by 4% to $3.67 billion versus $3.54 billion expected.

— Total product revenues rose by 4% driven by growth in multiple sclerosis drugs, spinal muscular atrophy drug Spinraza, biosimilars Benepali, Imraldi, and Flixabi.

— Research and development expense rose by 13% due to the inclusion of charges related to Samsung Bioepis transaction, related to the option exercise with Ionis Pharmaceuticals, and related to collaboration agreements with CAMP24 Therapeutics and Catalyst Biosciences.

— Looking ahead into the full year 2020, the company expects revenue in the range of $14-14.3 billion and adjusted earnings in the range of $31.50-33.50 per share. Analysts expect EPS of $33.03 on revenue of $14.06 billion.

— The earnings are anticipated to be in the range of $29.50-31.50 per share for the full year.

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips.

Related Post